| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
IND Submission example | IND | — | Subscribe to access the data. | CRISPR-Based Gene Editing Therapies | Rare Diseases | ||
IND Submission example | IND | — | Subscribe to access the data. | CRISPR-Based Gene Editing Therapies | Rare Diseases | ||
IND Submission example | IND | — | Subscribe to access the data. | CRISPR-Based Gene Editing Therapies | Rare Diseases |
Recent Updates
Recently added Catalysts
Beam Therapeutics Inc.$32.68
-3.12 (-8.71%)
D 34Pipeline Score Richly Valued Biotech · Commercial
Market Cap
2.98 B
EPS
-0.64
P/E Ratio
-45.2 $
Value Trade
33.82 M
SEC Financials
Q1 2026Dilution Risk
Revenue
31.74 M
R&D Expenses
104.52 M
Operating CF
-128.51 M
Total Assets
1.48 B
Total Liabilities
316.36 M
Equity
1.16 B
D/E Ratio
12,345
-0.31 %
Week
-8.5 %
1 Month
0.49 %
3 Month
39.64 %
6 Month
-60.78 %
5 Year
19.33 %
All Time
Cash Data
Cash Position
1.21 B
Monthly Burn
42.84 M
Runway
26.4 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
2.83 M
52 Week Range
15.60 - 36.44
% held by Insiders
8.89 %
% held by Institutions
96.63 %
Enterprise Value
2.02 B
Total Shares
101.84 M
Short %
28.69 %
Float Shares
79.74 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Beam Therapeutics Inc.
275Total events
5Upcoming
41Tier-1 (high impact)
2020 – 2029Coverage
Upcoming catalysts 5
Event history 270
Jul 8, 2026
▲IP Litigation RulingPM647IP / Competition
Arbitration tribunal declares PM647 within Prime Medicine's Field, no damages owed to Beam
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
Q3 2026
◆Enrollment MilestoneBEAM-302Trial
Pivotal cohort initiation expected in second half of 2026
alpha-1 antitrypsin deficiency (AATD)source ↗
Q3 2026
◆IND SubmissionPM647IND
IND and/or CTA filing for PM647 planned in Q3 2026
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
May 18, 2026
◆Oral PresentationBEAM-302Presentation
Presentation at ATS International Conference 2026 featuring BEAM-302 clinical data
alpha-1 antitrypsin deficiency (AATD)source ↗
Apr 1, 2026
▲Publicationristo-celPresentation
BEACON trial data published in New England Journal of Medicine
sickle cell disease (SCD)source ↗
Q2 2026
●Trial CompletionBEAM-103Trial
Dosing completion expected in first half of 2026
healthy volunteer (ESCAPE)source ↗
Q2 2026
Mar 2026
▲Topline ReadoutBEAM-302Clinical Data
Updated safety and efficacy data for BEAM-302 announced
alpha-1 antitrypsin deficiency (AATD)source ↗
Feb 24, 2026
▲Equity OfferingCorporate
Strategic financing agreement with Sixth Street for up to $500 million non-dilutive capital
Feb 24, 2026
▲Enrollment UpdateBEAM-301Trial
Enrollment initiated in second cohort of BEAM-301 trial
Glycogen Storage Disease Type Ia (GSDIa)source ↗
Drug Pipeline Intelligence
D34
Pipeline Score $305M
Pipeline ValueRichly Valued
Valuation Signal5
Drugs Scored0.1x
rNPV / MCap Top 46%
Small Cap (rank 493 of 911)
Percentile RankBeam Therapeutics Inc. faces pipeline headwinds (34/100), with $469M risk-adjusted pipeline value, led by BEAM-101 in Sickle Cell Disease (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BEAM-101 Monoclonal antibody | Sickle Cell Disease | Phase 1 | NCT05456880 | 40% | $246M | ACTIVE NOT_RECRUITING | 15 | SLOW | D (24) | Feb 1, 2028 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BEAM-302 RMATOrphan | alpha-1 antitrypsin deficiency (AATD) | Phase 1/2 | 2026-05-07 | 60 mg Selected as Optimal Biological Dose; robust increases in total AAT; well-tolerated safety profile; decreases in mutant Z-AAT; new production of corrected M-AAT Read More | Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, Read More | |
BEAM-302 RMATOrphan | alpha-1 antitrypsin deficiency (AATD) | Phase 1/2 | 2026-05-07 | 60 mg Selected as Optimal Biological Dose; robust increases in total AAT; well-tolerated safety profile; decreases in mutant Z-AAT; new production of corrected M-AAT Read More | Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, Read More | |
BEAM-302 RMATOrphan | alpha-1 antitrypsin deficiency (AATD) | Phase 1/2 | 2026-05-07 | 60 mg Selected as Optimal Biological Dose; robust increases in total AAT; well-tolerated safety profile; decreases in mutant Z-AAT; new production of corrected M-AAT Read More | Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BEAM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BEAM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BEAM▼ -8.7%today
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
Prime Medicine has successfully resolved its arbitration with Beam Therapeutics regarding the development of PM647, an investigational drug for Alpha-1 Antitrypsin Deficiency (AATD). The arbitration tribunal confirmed that PM647 falls within Prime Medicine's rights under their collaboration agreement, and no damages are owed to Beam. Prime Medicine plans to file for an IND or CTA for PM647 in Q3 2026, with initial clinical data anticipated in 2027.
Read more →BEAMBeam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile,
Beam Therapeutics has reported promising first quarter 2026 financial results and advancements in its clinical trials. The topline data for BEAM-302 in alpha-1 antitrypsin deficiency indicates a strong safety and efficacy profile, with plans to initiate a pivotal cohort later this year. Additionally, the company anticipates filing a Biologics License Application for risto-cel in sickle cell disease by year-end 2026. Beam's financial resources are robust, with $1.2 billion in cash, ensuring operational stability through mid-2029.
Read more →BEAM▲ +14%on this news
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) New Program Designed as Platform-based Approach for Direct Co
Beam Therapeutics has reported its financial results for Q4 and year-end 2025 while announcing the introduction of BEAM-304, a new program targeting phenylketonuria (PKU). This program aims to utilize advanced base editing technology to correct mutations associated with PKU, offering potential long-term solutions for patients. Additionally, Beam's financial strategy includes a significant non-dilutive capital investment to support its development efforts, including a Biologics License Application for risto-cel expected by the end of 2026. The company is well-positioned for clinical and regulatory milestones over the next few years.
Read more →BEAM▲ +22.3%on this news
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition Alignment Re
Beam Therapeutics announced its strategic priorities for 2026, focusing on its liver-targeted genetic disease and hematology programs. The company has aligned with the FDA on a potential accelerated approval pathway for BEAM-302, targeting Alpha-1 Antitrypsin Deficiency, and plans to submit a Biologics License Application for its risto-cel therapy by late 2026. Beam's strong financial position with $1.25 billion in cash is expected to support operations and facilitate the progress of its clinical programs through 2029. The company continues to innovate in the field of precision genetic medicines, showcasing advancements in their ongoing trials and pipeline development.
Read more →BEAM▼ -6.2%on this news
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency O
Beam Therapeutics has reported its third-quarter 2025 financial results, highlighting continued progress in its clinical trials, including BEAM-302 and BEAM-101. The company has a robust cash position of $1.1 billion, expected to fund operations until 2028, amidst ongoing research efforts in alpha-1 antitrypsin deficiency and sickle cell disease. Additionally, Beam is involved in a strategic acquisition scenario with Orbital Therapeutics, potentially enhancing its market position, but faces challenges with ongoing financial losses and rising R&D expenditures. Updated data presentations are scheduled for upcoming industry events, signaling active engagement in the biotech field.
Read more →BEAMBeam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Contin
Beam Therapeutics released its second quarter 2025 financial results, highlighting significant clinical progress in its BEAM-302 trial for alpha-1 antitrypsin deficiency (AATD) with 17 patients dosed. The company reported durable correction of the disease-causing mutation and emphasized a well-tolerated safety profile. Beam also indicated cash reserves to sustain operations through 2028, with upcoming data expected from BEAM-302 and BEAM-101 clinical trials by early and late 2025 respectively. Additionally, BEAM-302 has received RMAT and orphan drug designations from the FDA, underscoring its potential for AATD treatment.
Read more →BEAM▼ -19.3%on this news
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam's Second Clinical Stage In Vi
Beam Therapeutics reported its first quarter 2025 financial results, highlighting significant clinical advancements and a solid financial position. The company announced the dosing of the first patient in the Phase 1/2 study of BEAM-301 for glycogen storage disease type Ia and continued progress in its BEAM-302 program for alpha-1 antitrypsin deficiency. Financially, Beam ended the quarter with $1.2 billion in cash and equivalents, supported by a recent $500 million financing. Additionally, updates on other clinical programs are anticipated in 2025, presenting opportunities for further advancements.
Read more →BEAM▼ -9.8%on this news
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation Single Do
Beam Therapeutics announced promising initial results from their Phase 1/2 trial of BEAM-302 for treating Alpha-1 Antitrypsin Deficiency (AATD). Initial data shows that BEAM-302, after a single dose, can significantly increase levels of functional Alpha-1 Antitrypsin while reducing the levels of harmful mutant proteins. The treatment appears to be well tolerated, with no serious adverse effects reported. Further results are anticipated at a medical conference in late 2025 as the trial continues.
Read more →BEAM▼ -9.8%on this news
Beam Therapeutics Announces Pricing of Underwritten Offering Cambridge, Mass.
Beam Therapeutics announced the pricing of an underwritten offering of over 16 million shares priced at $28.48 each, projected to raise about $500 million. The proceeds will be aimed at advancing their base editing technology and funding various clinical trials, such as for alpha-1 antitrypsin deficiency and sickle cell disease. The offering is expected to finalize on March 11, 2025, subject to standard closing conditions. Major financial institutions, including J.P. Morgan and Citigroup, are managing the offering.
Read more →BEAMBeam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial of BEAM-101; Dosing of 3
Beam Therapeutics has reported its fourth-quarter and year-end financial results for 2024, achieving its adult enrollment target in the BEACON trial for sickle cell disease therapy BEAM-101. The company is set to present updated data from this trial in mid-2025 while also progressing on other therapies, including BEAM-302 for alpha-1 antitrypsin deficiency. Although the company holds $850.7 million in cash to sustain operations through 2027, it experienced notable net losses and a decrease in cash reserves compared to the previous year. The upcoming milestones and existing cash position indicate a well-structured plan moving forward in 2025.
Read more →BEAMPRECISION GENETIC MEDICINES THROUGH BASE EDITING NASDAQ: BEAM January 2025 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Secu
Beam Therapeutics is showcasing its advancements in precision genetic medicines through base editing, highlighting the progress of its pipeline candidates such as BEAM-101, BEAM-302, and others. The company's initiatives aim to provide potential one-time curative therapies for diseases like sickle cell disease and alpha-1 antitrypsin deficiency. While Beam has a robust financial position to support its operations, it acknowledges various risks associated with regulatory approvals and clinical trial timelines. The company is set to present significant data and updates throughout 2025, reflecting its leadership in the gene editing field.
Read more →BEAMBeam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting All Seven Patients Treated with BEAM-101 Achieved Hemogl
Beam Therapeutics has announced promising data from the BEACON Phase 1/2 clinical trial of its investigational therapy, BEAM-101, for patients with sickle cell disease. All seven patients in the study experienced a robust increase in fetal hemoglobin and reductions in sickle hemoglobin, without reports of vaso-occlusive crises following treatment. Initial safety results are consistent with existing therapies, and further data are expected to provide insights into the long-term benefits of BEAM-101. Beam plans to present additional findings during the upcoming American Society of Hematology annual meeting.
Read more →BEAM▲ +5.5%on this newsshared move
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer Cambridge, Mass.
Beam Therapeutics has appointed Sravan K. Emany as the new Chief Financial Officer, effective December 19, 2024. Emany brings extensive experience from his previous roles, notably as CFO at Ironwood Pharmaceuticals and various positions in investment banking. The appointment is expected to enhance Beam's capital formation strategy as the company advances its clinical programs in genetic medicine. Beam's CEO John Evans highlighted Emany's expertise in value creation within the life sciences as a key asset for the company's growth.
Read more →BEAMBeam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader Cambridge, Mass.
Beam Therapeutics has appointed Chirfi Guindo, a seasoned executive with extensive experience in the pharmaceutical industry, to its Board of Directors. Guindo, who has been with Merck & Co., Inc. for over 25 years, is expected to contribute valuable strategic insights to Beam as it continues to innovate in the field of precision genetic medicines through base editing. His leadership is anticipated to play a crucial role in enhancing the company's growth and mission of providing transformative therapies for serious diseases.
Read more →BEAMBeam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at Ameri
Beam Therapeutics has reported encouraging third-quarter 2024 financial results, highlighting significant advancements in its clinical trials for BEAM-101 and BEAM-302. The company has enrolled 35 patients in the BEACON Phase 1/2 trial for sickle cell disease and completed dosing for the initial cohort in the BEAM-302 trial targeting alpha-1 antitrypsin deficiency. Beam ended the quarter with a robust cash position of $925.8 million, expected to fund operations and advancements through 2027. The upcoming American Society of Hematology meeting will showcase initial data for BEAM-101 and ESCAPE, marking a pivotal moment for the company.
Read more →BEAMBeam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting I
Beam Therapeutics announced the acceptance of multiple presentations at the upcoming American Society of Hematology (ASH) Annual Meeting, showcasing initial clinical data for BEAM-101, a potential treatment for sickle cell disease. The data from the BEACON Phase 1/2 trial highlights the promising safety and efficacy of BEAM-101, showing significant induction of fetal hemoglobin and reduction of sickle hemoglobin. Additionally, preclinical findings from the ESCAPE study suggest a novel approach to stem cell transplants without chemotherapy, marking a potentially pivotal advancement in hematology treatment.
Read more →BEAMQ3 Financial Results & ASH Abstracts Investor Webcast
Beam Therapeutics reported their Q3 financial results, highlighting significant milestones in their clinical trials for gene editing treatments, particularly for sickle cell disease and alpha-1 antitrypsin deficiency. They have completed first cohort dosing in BEAM-302 and enrolled patients for BEAM-101 and BEAM-301 trials. Additionally, Beam is preparing to present four abstracts at the upcoming American Society of Hematology Annual Meeting. The company has a robust financial position with ample cash reserves projected to last until 2027.
Read more →BEAMBeam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results U.S. Food and Drug Administration Cleared Investigational New Drug (IND) Application for BEAM-301 in Glycogen Storage Disease Type Ia (
Beam Therapeutics has announced significant pipeline updates and financial results for Q2 2024, highlighting the successful FDA clearance of the IND application for BEAM-301 targeting glycogen storage disease type Ia. The company reported over 20 patients enrolled in the BEACON trial for BEAM-101, with initial clinical data set for presentation at the upcoming ASH Annual Meeting. Despite a net loss of $91.1 million for the quarter, Beam maintains a robust cash position of $1 billion, which is projected to sustain operations into 2027. The company is also actively advancing its BEAM-302 trial in alpha-1 antitrypsin deficiency with initial data expected next year.
Read more →BEAMBeam Therapeutics Announces Transition of Chief Financial Officer Cambridge, Mass.
Beam Therapeutics announced the departure of CFO Terry-Ann Burrell, effective August 9, 2024, to join JPMorgan Chase. The company is initiating a search for her successor, recognizing Burrell's significant contributions, particularly during its IPO. CEO John Evans praised her leadership, highlighting the company's strong capital and clinical portfolio. Despite the transition, Beam expresses confidence in its future and the potential of its base editing technologies.
Read more →BEAMBeam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results Dosing Completed for Sentinel Cohort of BEACON Phase 1/2 Trial of BEAM-101 in Severe Sickle Cell Disease; Expansion Cohort Initiated Cli
Beam Therapeutics has reported significant advancements in its clinical trials, particularly with BEAM-101 for severe sickle cell disease, where dosing for the sentinel cohort is complete and an expansion cohort is set to begin. The company has also secured clearance for a Phase 1/2 trial of BEAM-302 aimed at treating alpha-1 antitrypsin deficiency. Financially, Beam ended Q1 2024 with $1.1 billion in cash, which is projected to support operations until 2027. However, the net loss for the quarter has risen, prompting concerns about financial sustainability amid increasing expenses.
Read more →BEAM▲ +25.9%on this news
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle
Beam Therapeutics has reported its financial results for the fourth quarter and year-end 2023, highlighting a strong cash position of $1.2 billion. The company is progressing with its BEACON trial for BEAM-101 in severe sickle cell disease, with initial data expected in the second half of 2024. Additionally, Beam plans to initiate the Phase 1 trial for BEAM-302, targeting alpha-1 antitrypsin deficiency, in the first half of 2024. Overall, the company is optimistic about achieving its milestones and advancing its genetic medicine portfolio in 2024.
Read more →BEAM▲ +6.9%on this news
PRECISION GENETIC MEDICINES THROUGH BASE EDITING JANUARY 2024 NASDAQ: BEAM Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Secu
Beam Therapeutics is advancing its pipeline in precision genetic medicines through base editing, with significant catalysts expected in 2024, including expansions in clinical trials and new submissions. The company highlighted key achievements in 2023, including the first patients dosed with base edited therapies and regulatory advancements. Although optimistic about its innovative capabilities, Beam acknowledges various risks, including the development timeline and funding availability for its product candidates. Overall, Beam appears committed to providing transformative therapies for serious diseases, particularly Sickle Cell Disease (SCD) and Alpha-1 Antitrypsin Deficiency (AATD).
Read more →BEAM▲ +5.3%on this news
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
Beam Therapeutics has appointed Christi Shaw, a seasoned biotech executive, to its board of directors. Shaw, who previously led Kite as CEO, possesses extensive experience in transforming scientific innovations into viable treatments. Her expertise is expected to help propel Beam’s initiatives in advancing precision genetic medicines and base editing technologies.
Read more →BEAM▼ -8.4%on this news
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results Recent Portfolio Prioritization Focuses Business on Key Near-term Value Drivers and Long-term Growth of Precision Genetic M
Beam Therapeutics has reported third quarter 2023 financial results and updates on its pipeline and business strategy. The company is focusing on prioritizing near-term value drivers while advancing clinical trials, particularly for BEAM-101 in sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency. A recent collaboration with Eli Lilly could generate up to $600 million, bolstering Beam's financial capacity. The company also announced the initiation of GMP operations at its manufacturing facility in North Carolina, enhancing its production capabilities for gene editing therapies.
Read more →BEAM▲ +10.6%on this news· ran to +28% by day 3
Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, E
Beam Therapeutics has announced an agreement with Eli Lilly, whereby Lilly will acquire Beam's opt-in rights to Verve Therapeutics' base editing programs for cardiovascular disease. Beam will receive a $250 million combined upfront payment and equity investment, with potential for up to $600 million in total deal consideration based on future milestones. This partnership is expected to enhance Beam's financial position, extending its cash runway to the second half of 2026. The collaboration aims to leverage both companies' expertise in developing novel therapeutic options for cardiovascular disease.
Read more →BEAM▼ -11.7%on this news
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the initiation, timing, prog
Beam Therapeutics is advancing its genetic medicine pipeline through base editing technologies aimed at addressing various diseases, including sickle cell disease and several genetic disorders. The company is expanding clinical trials, such as the BEACON trial and BEAM-201 trial, with the goal of demonstrating the efficacy and safety of its precision therapies. However, the future outcomes of these initiatives are inherently uncertain and subject to various operational and regulatory risks. Beam also highlights its strategy to develop potential life-long cures while navigating financial and competitive challenges.
Read more →BEAMBeam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate E
Beam Therapeutics announced its second quarter 2023 financial results alongside updates on its clinical pipeline, especially regarding the BEACON trial for BEAM-101 in sickle cell disease. The trial is progressing well, with patient consented numbers sufficient to commence both the sentinel and expansion cohorts. Additionally, the company has consented its first patient for the BEAM-201 trial, with dosing anticipated in the third quarter. Financially, Beam holds $1.1 billion in cash, ensuring continued investment in its innovative gene editing programs.
Read more →BEAMBeam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-T
Beam Therapeutics has reported its first quarter 2023 financial results alongside updates on its clinical pipeline. The company is progressing in its BEACON clinical trial for sickle cell disease with additional sites and patient enrollment. Furthermore, Beam is set to initiate a trial for BEAM-201 in blood cancer this year and is advancing its in vivo base editing programs. Despite a notable net loss and increased research costs, the company remains well-capitalized with $1.1 billion in cash to support its strategic initiatives.
Read more →BEAMBeam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones Advancing Pipeline of Wholly Owned Base Editing Therapeutics with Four Development-stage Programs Expandi
Beam Therapeutics has reported its fourth quarter and year-end 2022 financial results while reaffirming future milestones for its base editing therapeutics. The company announced significant advances in its pipeline, including clinical developments for sickle cell disease and T-cell leukemia therapies. With a robust cash position of $1.1 billion, Beam appears well-equipped to pursue its strategic initiatives through 2025. However, the company also noted a considerable net loss in 2022, highlighting ongoing financial challenges as it moves forward with its innovative therapies.
Read more →BEAM▼ -11.4%on this news
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Str
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results Patient Recruitment Underway in BEACON Clinical Trial of BEAM-101 for Treatment of Sickle Cell Disease as Part of Wave 1 Strategy Execution IND-enabling Studies Underway for BEAM-301
Read more →BEAMBeam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 on Track for Second Half of 2022 BEAM-201 IND Subm
Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 on Track for Second Half of 2022 BEAM-201 IND Submitted to FDA; Currently on Clinical Hold BEAM-102 IND Sub
Read more →BEAM▼ -6.6%on this news
Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application
Beam Therapeutics Announces FDA Clinical Hold on BEAM-201 IND Application CAMBRIDGE, Mass., August 1, 2022 Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that on Friday, July 29, 2022, t
Read more →BEAM▼ -6.7%on this news
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-tr
Beam Therapeutics Announces Pipeline and Business Highlights and Reports First Quarter 2022 Financial Results BEAM-101 Patient Enrollment, BEAM-102 and BEAM-201 IND Submissions and BEAM-301 IND-Enabling Studies All On-track for Second Half of 2022 Natural History Study Initiate
Read more →BEAMBeam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results Research Collaboration with Pfizer Underway, with Upfront and Potential Mileston
Beam Therapeutics Reports Pipeline and Business Highlights, Planned 2022 Milestones and Fourth Quarter and Full Year 2021 Financial Results Research Collaboration with Pfizer Underway, with Upfront and Potential Milestone Payments of Up to $1.35 Billion Executing First Wave of
Read more →BEAM▲ +10.6%on this news
Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Al
Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease BEAM-102 IND-Enabling Studies Also Underway CAMBRIDGE, Mass., Nov. 8, 2021 -Beam Therapeu
Read more →BEAMBeam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editi
Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of IND-Enabling Studies
Read more →BEAMBeam Therapeutics Presents LNP Formulation Data at ASGCT and Reports First Quarter 2021 Financial Results Data from Beam's Novel LNP-mRNA Formulation Demonstrates In Vivo Editing in Liver Cells of Non-human Primates Up t
Beam Therapeutics Presents LNP Formulation Data at ASGCT and Reports First Quarter 2021 Financial Results Data from Beam's Novel LNP-mRNA Formulation Demonstrates In Vivo Editing in Liver Cells of Non-human Primates Up to 52% Company On-track to Submit First IND for BEAM-101 in
Read more →BEAMBeam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021 Acquisition of Guid
Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021 Acquisition of Guide Therapeutics Supports Targeting of Diverse Tissues for I
Read more →BEAMBeam Therapeutics Announces Acquisition of Guide Therapeutics GuideTx s Proprietary LNP Screening Technology and Lipid Library Supports Expanded Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing
Beam Therapeutics Announces Acquisition of Guide Therapeutics GuideTx s Proprietary LNP Screening Technology and Lipid Library Supports Expanded Targeting of Diverse Tissues for In Vivo Delivery of CAMBRIDGE, Mass., Feb. 23, 2021 - Beam Therapeutics Inc. (Nasdaq: BEAM), a biote
Read more →BEAMBeam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors
Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) Beam Therapeutics Inc. (Nasdaq: BEAM) (the Company ), a biotechnology company developing precision genetic medicines through base editi
Read more →BEAMThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect, among other things, our current expectations and
PRECISION GENETIC MEDICINES THROUGH BASE EDITING Beam Therapeutics NASDAQ: BEAM Exhibit 99.1 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect, among other thi
Read more →BEAMBeam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Candidate for Treatment of T-ALL
Beam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Candidate for Treatment of T-ALL; First Cell Therapy Featuring Four Simultaneous Genetic Ed
Read more →BEAMBeam Therapeutics Announces First Development Candidates for Sickle Cell Disease and Reports Second Quarter 2020 Results BEAM-101 and BEAM-102 Named as Development Candidates Targeting Distinct Approaches to Treating Sic
Beam Therapeutics Announces First Development Candidates for Sickle Cell Disease and Reports Second Quarter 2020 Results BEAM-101 and BEAM-102 Named as Development Candidates Targeting Distinct Approaches to Treating Sickle Cell Disease Lease Agreement Signed to Build In-house
Read more →BEAMBeam Therapeutics Reports Additional Data at ASGCT Annual Meeting and First Quarter 2020 Financial Results Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functio
Beam Therapeutics Reports Additional Data at ASGCT Annual Meeting and First Quarter 2020 Financial Results Alpha-1 Antitrypsin Deficiency Program Demonstrates More than Four-Fold Increase in Circulating Levels of Functional Protein Following Durable Direct Correction In Vivo No
Read more →BEAMBeam Therapeutics Reports Business Updates and Full Year 2019 Financial Results Successful Initial Public Offering Completed and Continued Advancement of Broad Portfolio of Novel Base Editing Programs
Beam Therapeutics Reports Business Updates and Full Year 2019 Financial Results Successful Initial Public Offering Completed and Continued Advancement of Broad Portfolio of Novel Base Editing Programs CAMBRIDGE, Mass., March 30, 2020 - Beam Therapeutics Inc. (Nasdaq: BEAM), a b
Read more →Competitive Position
How BEAM ranks across every disease it competes inCompetitive Position is a premium feature
See how BEAM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial